TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Calliditas Therapeutics AB
Closing information (x1000 NOK)
| Closing information | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
2,060,726
|
1,222,616
|
759,453 |
| Financial expenses |
563,077
|
115,839
|
35,632 |
| Earnings before taxes |
-662,095
|
-462,973
|
-387,273 |
| EBITDA |
-138,441
|
-361,106
|
-386,907 |
| Total assets |
2,529,093
|
1,883,474
|
1,847,342 |
| Current assets |
1,242,412
|
1,291,769
|
1,335,822 |
| Current liabilities |
744,009
|
412,450
|
307,639 |
| Equity capital |
170,374
|
339,169
|
724,818 |
| - share capital |
2,523
|
2,414
|
2,254 |
| Employees (average) |
62
|
181
|
86 |
Financial ratios
| Fiscal year | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
6.7%
|
18.0%
|
39.2% |
| Turnover per employee |
33,238
|
6,755
|
8,831 |
| Profit as a percentage of turnover |
-32.1%
|
-37.9%
|
-51.0% |
| Return on assets (ROA) |
-3.9%
|
-18.4%
|
-19.0% |
| Current ratio |
167.0%
|
313.2%
|
434.2% |
| Return on equity (ROE) |
-388.6%
|
-136.5%
|
-53.4% |
| Change turnover | |||
| Change turnover % |
50%
|
250% | |
| Chg. No. of employees | |||
| Chg. No. of employees % |
110%
|
54% |
Total value of public sale
| Fiscal year | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.